Nasal formulation development at MedPharm begins with pre-formulation studies to define feasibility and guide formulation strategy.
Pre-formulation studies evaluate:
The delivery device is considered early in development due to its critical role in nasal deposition and performance.
Excipients are selected to ensure:
Pulmonary formulation development follows a similar approach, beginning with pre-formulation studies and early device selection.
Device choice depends on delivery via:
When the optimal delivery route is unknown, feasibility studies can be performed. For rapid proof of concept, nebulizers are often the most efficient approach due to their strong influence on drug delivery performance.
MedPharm’s MedCast™ nasal cast model is built from head CT scans and 3D printed, enabling rapid customization of regions of interest for specific delivery strategies.
The most compatible material is selected for cast construction. MedCast™ enables quantitative assessment of drug deposition across defined nasal regions, providing a closer-to-real-world evaluation of formulation and device performance.
This model uses primary human nasal epithelial cells grown on permeable inserts and differentiated at an air–liquid interface.
The resulting tissue:
These features recreate the unique respiratory barrier for evaluating nasal drug delivery and permeation.
MedPharm has developed a reconstructed fibrotic bronchial tissue model for Idiopathic Pulmonary Fibrosis, a chronic and progressive lung disease characterized by fibrosis and impaired breathing.
This model enables evaluation of new IPF therapies in a clinically relevant in vitro system.
